News

GSK’s Jemperli Gets FDA Priority Review for Locally Advanced Rectal Cancer

If approved, Jemperli could eliminate the need for chemotherapy, radiation, and surgery for some patients with dMMR/MSI-H locally advanced rectal cancer, said GSK.